Molecular mechanisms of DNA damage by PAHs

PAHs 损伤 DNA 的分子机制

基本信息

  • 批准号:
    7302444
  • 负责人:
  • 金额:
    $ 41.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Molecular mechanisms of DNA damage by PAHs. Polycyclic aromatic hydrocarbons (PAHs) can be a activated to reactive intermediates capable of inducing DNA damage by three major pathways. First, cytochromes P450 (P450) 1A1 and CYP1B1 can convert frans-dihydrodiols to (+)-a/tf/-diol-epoxides, which yield primarily a stable (+)-anft-fr"ans-N2-2'-deoxyguanosine (dGuo) adduct. Second, CYP peroxidase can convert the parent PAH to radical cations that form depurinating N7- and C8-guanine (Gua) and N7-adenine (Ade) adducts. Third, AKRs can convert trans-dihydrodiols to o-quinones, which redox cycle to generate reactive oxygen species (ROS). The ROS can directly modify DNA to form 7,8-dihydro-8-oxo-2'- deoxyguanosine (8-oxo-dGuo) as well as inducing the formation of lipid hydroperoxides. Lipid hydroperoxides undergo homolytic decomposition to form the bifunctional electrophile 4-oxo-2-nonenal, which then covalently modify DNA to form a heptanone-etheno-dGuo (HsdGuo)-adduct. We propose to use the ubiquitous environmental carcinogen benzo[a]pyrene (B[a]P) as a model PAH to explore the role of environmental exposure to PAHs in the induction of oxidative stress and formation of DNA-adducts. We have developed a stable isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) method for the specific analysis of (+)-anf/-frans-B[a]P-7,8,9,10-tetrahydro-7,8- diol-9,10-epoxide-N2-dGuo-adduct and quantified the formation of this adduct in four different human lung- derived cell lines. These studies have unexpectedly revealed that up-regulation of P450s 1A1 and 1B1 has a protective effect on DNA damage. We now propose to explore the molecular basis of this exciting new finding. Immunoaffinity stable isotope dilution LC-MRM/MS methodology has also recently revealed that lipid oxidation-derived HedGuo is present in the urine of subjects exposed to high levels of B[a]P through smoking. These studies will be extended to a B[a]P-exposed mouse model in which the B[a]P-derived urinary metabolites and DNA-adducts will be quantified together with urinary lipid oxidation products and HedGuo. Translational research will be conducted by monitoring the exposure of human populations to B[a]P through analysis of urinary B[a]P metabolites. The effects of this exposure will be assessed by monitoring urinary B[a]P-DNA-adducts, HedGuo, and oxidized lipids in the same subjects. We propose to address the following hypotheses: (1) P450 1A1 and 1B1 protect against DNA damage by facilitating removal of B[a]P metabolites through phase II enzymes. (2) Transport into the nucleus is an important determinant of DNA damage. (3) Analysis of oxidized lipids and B[a]P metabolites will define the relationship between oxidative stress and B[a]P exposure. (4) Quantitative analysis of urinary B[a]P- and a lipid oxidation-derived DNA-adducts will provide insight into the amount of DNA damage that has occurred in an animal model and in human populations exposed to B[a]P. The proposed research will be conducted under four specific aims. Aim 1. To analyze lipid oxidation- and B[a]P-derived DNA-adducts in cellular models of impaired nuclear transport. Aim 2. To develop stable isotope dilution LC-electron capture atmospheric pressure chemical ionization/MRM/MS and immunoaffinity LC-MRM/MS methodology for analysis of urinary B[a]P metabolites and B[a]P-derived DNA-adducts, respectively. Aim 3. To quantify urinary oxidized lipids, HedGuo, B[a]P metabolites, and B[a]P-derived DNA-adducts in a mouse model exposed to B[a]P. Aim 4. To quantify urinary oxidized lipids, HedGuo, B[a]P metabolites, and B[a]P-derived DNA-adducts in smoking and non-smoking human populations exposed to environmental B[a]P. Successful completion of the proposed research will permit provide a new approach and novel methodology for determining the inter-individual risk factors for DNA damage, which result from environmental exposure to B[a]P.
描述(由申请人提供):PAHS DNA损伤的分子机制。多环芳烃(PAHS)可以激活到能够通过三个主要途径诱导DNA损伤的反应性中间体。 First, cytochromes P450 (P450) 1A1 and CYP1B1 can convert frans-dihydrodiols to (+)-a/tf/-diol-epoxides, which yield primarily a stable (+)-anft-fr"ans-N2-2'-deoxyguanosine (dGuo) adduct. Second, CYP peroxidase can convert the parent PAH to radical cations that form depurinating N7和C8-瓜氨酸(GUA)和N7-腺嘌呤(ADE)加合物。脂质氢过氧化物的形成。 PAH模型探讨了环境暴露于PAHS在诱导氧化应激和DNA添加剂形成中的作用。 We have developed a stable isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) method for the specific analysis of (+)-anf/-frans-B[a]P-7,8,9,10-tetrahydro-7,8- diol-9,10-epoxide-N2-dGuo-adduct and quantified the formation of this adduct in four different human lung- derived cell lines.这些研究意外地表明,P450S 1A1和1B1的上调对DNA损伤具有保护作用。现在,我们建议探索这一令人兴奋的新发现的分子基础。免疫亲和力稳定的同位素稀释LC-MRM/MS方法论最近还显示,脂质氧化衍生的hedguo存在于暴露于高水平B [A] P的受试者的尿液中。这些研究将扩展到B [a] P举动的小鼠模型,其中B [A] P衍生的尿尿代谢产物和DNA-ADDUCT将与尿脂质氧化产物和Hedguo一起量化。翻译研究将通过通过分析尿B [A] P代谢物的分析来监测人群对B [A] P的暴露。该暴露的影响将通过监测同一受试者中的尿B [A] P-DNA-ADDUCTS,HEDGUO和氧化脂质进行评估。我们建议解决以下假设:(1)P450 1A1和1B1通过促进通过II期酶促进B [A] P代谢产物的去除来防止DNA损伤。 (2)进入细胞核是DNA损伤的重要决定因素。 (3)分析氧化脂质和B [A] P代谢物将定义氧化应激与B [A] P暴露之间的关系。 (4)对尿液B [A] P-和脂质氧化衍生的DNA添加剂的定量分析将洞悉动物模型和暴露于B [A] p的人群中发生的DNA损伤量。拟议的研究将以四个特定目的进行。目的1。分析核转运受损的细胞模型中的脂质氧化和B [A] P衍生的DNA添加剂。目的2。为了开发稳定的同位素稀释LC-电子捕获大气压化学电离/MRM/MS和免疫亲和力LC-MRM/MS方法,用于分析尿液B [A] P代谢物和B [A] P衍生的DNA- adducts。目标3。在暴露于B [a] p的小鼠模型中,要量化尿氧化的脂质,Hedguo,Hedguo,B [A] P代谢产物和B [A] P衍生的DNA- adducts。目的4。用于量化尿液氧化的脂质,hedguo,b [a] p代谢产物和B [A] P衍生的DNA添加剂在吸烟和未吸烟的人群中暴露于环境B [a] p [a] p的人群中。拟议的研究的成功完成将允许提供一种新方法和新方法来确定DNA损伤的个体间危险因素,这是由于环境暴露于B [a] p所致。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian Alexander Blair其他文献

Ian Alexander Blair的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian Alexander Blair', 18)}}的其他基金

Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10337249
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10115684
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10565951
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10356088
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10582596
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10117295
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9530878
  • 财政年份:
    2014
  • 资助金额:
    $ 41.94万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9041609
  • 财政年份:
    2014
  • 资助金额:
    $ 41.94万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    8651082
  • 财政年份:
    2014
  • 资助金额:
    $ 41.94万
  • 项目类别:
Core N: MOLECULAR PROFILING
核心 N:分子谱分析
  • 批准号:
    8126787
  • 财政年份:
    2012
  • 资助金额:
    $ 41.94万
  • 项目类别:

相似国自然基金

高通透孔道和精确分子取向识别印迹微球选择性分离纯化2'-脱氧腺苷的研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    64 万元
  • 项目类别:
    面上项目
以2ʹ-氯代喷司他丁与2ʹ-氨基-2ʹ-脱氧腺苷为模型的腺苷类抗生素组合的生物合成研究
  • 批准号:
    31970052
  • 批准年份:
    2019
  • 资助金额:
    56 万元
  • 项目类别:
    面上项目
基于MTH1底物设计的7-脱氮-2´-脱氧腺苷类似物的合成与抗肿瘤活性研究
  • 批准号:
    81903425
  • 批准年份:
    2019
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
乳液界面各向异性生长辅助构建单孔中空MMIPs选择性分离纯化2′-脱氧腺苷的研究
  • 批准号:
    21706099
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Mechanisms of HIV-1 Hypersensitivity to Islatravir
HIV-1 对 Islatravir 过敏的机制
  • 批准号:
    10548541
  • 财政年份:
    2022
  • 资助金额:
    $ 41.94万
  • 项目类别:
A dual-purpose hu-mouse model for evaluating SIV and HIV cure strategies
用于评估 SIV 和 HIV 治疗策略的双用途人鼠模型
  • 批准号:
    10652685
  • 财政年份:
    2022
  • 资助金额:
    $ 41.94万
  • 项目类别:
Mechanisms of HIV-1 Hypersensitivity to Islatravir
HIV-1 对 Islatravir 过敏的机制
  • 批准号:
    10731747
  • 财政年份:
    2022
  • 资助金额:
    $ 41.94万
  • 项目类别:
Long-Acting Prevention Implantable System (LAPIS) for HIV Pre-ExposureProphylaxis (PrEP)
用于 HIV 暴露前预防 (PrEP) 的长效预防植入系统 (LAPIS)
  • 批准号:
    10348177
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
Salvage of the sulfur and carbon byproducts of S-adenosylmethionine metabolism in pathogenic bacteria
病原菌中S-腺苷甲硫氨酸代谢的硫和碳副产物的回收
  • 批准号:
    10163801
  • 财政年份:
    2020
  • 资助金额:
    $ 41.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了